Oridonin inhibits aberrant AKT activation in breast cancer.
Sun B, Wang G, Liu H, Liu P, Twal WO, Cheung H, Carroll SL, Ethier SP, Mevers EE, Clardy J, Roberts T, Chen C, Li Q, Wang L, Yang M, Zhao JJ, Wang Q.
Sun B, et al.
Oncotarget. 2018 Feb 1;9(35):23878-23889. doi: 10.18632/oncotarget.24378. eCollection 2018 May 8.
Oncotarget. 2018.
PMID: 29844859
Free PMC article.